KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 103 filers reported holding KEROS THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $59,531,087 | -15.1% | 1,867,349 | +7.0% | 0.00% | 0.0% |
| Q2 2023 | $70,089,871 | -2.1% | 1,744,397 | +4.0% | 0.00% | 0.0% |
| Q1 2023 | $71,619,004 | -9.0% | 1,677,260 | +2.4% | 0.00% | 0.0% |
| Q4 2022 | $78,672,416 | +43.1% | 1,638,326 | +12.1% | 0.00% | 0.0% |
| Q3 2022 | $54,968,000 | +42.5% | 1,461,190 | +4.6% | 0.00% | +100.0% |
| Q2 2022 | $38,581,000 | -45.3% | 1,396,343 | +7.6% | 0.00% | -50.0% |
| Q1 2022 | $70,588,000 | -6.2% | 1,298,046 | +0.9% | 0.00% | 0.0% |
| Q4 2021 | $75,277,000 | +54.2% | 1,286,526 | +4.2% | 0.00% | +100.0% |
| Q3 2021 | $48,825,000 | -7.2% | 1,234,158 | -0.4% | 0.00% | 0.0% |
| Q2 2021 | $52,636,000 | -30.1% | 1,239,373 | +1.3% | 0.00% | -50.0% |
| Q1 2021 | $75,339,000 | -10.9% | 1,224,045 | +2.1% | 0.00% | -33.3% |
| Q4 2020 | $84,590,000 | +235.0% | 1,199,201 | +83.2% | 0.00% | +200.0% |
| Q3 2020 | $25,249,000 | +1.9% | 654,642 | -0.9% | 0.00% | 0.0% |
| Q2 2020 | $24,769,000 | – | 660,321 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 396,911 | $21,584,000 | 5.10% |
| Deep Track Capital, LP | 1,380,306 | $75,061,000 | 4.81% |
| Opaleye Management Inc. | 265,750 | $14,451,000 | 4.49% |
| Octagon Capital Advisors LP | 340,214 | $18,501,000 | 4.00% |
| First Light Asset Management, LLC | 658,145 | $35,790,000 | 3.16% |
| Altium Capital Management LP | 126,000 | $6,852,000 | 2.29% |
| Nantahala Capital Management | 816,830 | $44,419,000 | 1.96% |
| Orbimed Advisors | 1,679,417 | $91,327,000 | 1.48% |
| CHI Advisors LLC | 62,229 | $3,384,000 | 1.44% |
| Parkman Healthcare Partners LLC | 72,690 | $3,953,000 | 1.16% |